@article{55989fe607a44c56bcd26118e9bdba9e,
title = "Perspective from the 5th international pemphigus and pemphigoid foundation scientific conference",
abstract = "The 5th Scientific Conference of the International Pemphigus and Pemphigoid Foundation (IPPF), {"}Pemphigus and Pemphigoid: A New Era of Clinical and Translational Science{"} was held in Orlando, Florida, on May 15-16, 2018. Scientific sessions covered recent, ongoing, and future clinical trials in pemphigus and bullous pemphigoid, disease activity and quality of life instruments, and the IPPF Natural History Study. Furthermore, the meeting provided an opportunity to hear firsthand from patients, investigators, and industry about their experience enrolling for clinical trials.",
keywords = "Btk, Doxycycline, Eotaxin, FcRn, Fumarate, Leukotriene, Rituximab, T-cell",
author = "Jinmin Lee and Werth, {Victoria P.} and Hall, {Russell P.} and R{\"u}diger Eming and Fairley, {Janet A.} and Fajgenbaum, {David C.} and Harman, {Karen E.} and Jonkman, {Marcel F.} and Korman, {Neil J.} and Ludwig, {Ralf J.} and Murrell, {Dedee F.} and Philippe Musette and Naik, {Haley B.} and Sadik, {Christian D.} and Jun Yamagami and Yale, {Marc L.} and Payne, {Aimee S.}",
note = "Funding Information: The conference was made possible by the sponsorship of Principia Biopharma, Syntimmune, Eli Lilly, Genentech, Immune Pharmaceuticals, argenx, and the EveryLife Foundation for Rare Diseases. We are indebted to Patrick Dunn, Nelly Filippov, Becky Strong, and Amethyst Yale at the IPPF for coordinating the conference. Publisher Copyright: {\textcopyright} 2018 Lee, Werth, Hall, Eming, Fairley, Fajgenbaum, Harman, Jonkman, Korman, Ludwig, Murrell, Musette, Naik, Sadik, Yamagami, Yale and Payne.",
year = "2018",
doi = "10.3389/fmed.2018.00306",
language = "English",
volume = "5",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media S. A.",
number = "NOV",
}